DIRS.INFO The most relevant business & tech news

☆ Some smaller stocks could see big gains as the Fed cuts rates. Here are a few
▼ + stars: | 2024-09-21 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

Stocks with smaller market capitalizations are set to reap the benefits from the start of the Federal Reserve's latest rate-cutting campaign. Sarepta's total debt is more than one-and-a-half times bigger than its total equity. Civitas' total debt recently stood at about 79% of total equity. Chart's total debt currently eclipses its total equity by 1.4 times. "GTLS's core portfolio is comprised of natural gas, energy transition and renewables applications, where our outlook remains constructive," wrote analyst Devin McDermott.

Persons: Russell, Gavin Clark, Gartner, Clark, Zach Parham, Parham, Morgan Stanley, Devin McDermott Organizations: Dow Jones Industrial, Nasdaq, CNBC, Sarepta Therapeutics, ISI, Civitas Resources, Wednesday, JPMorgan, Civitas, Industries Locations: U.S, Cambridge, Sarepta, Friday's

☆ TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval
▼ + stars: | 2024-06-21 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approvalRitu Baral, TD Cowen Sr. Biotechnology Analyst, joins 'Closing Bell Overtime' to talk Sarepta's approval from the FDA for its Duchenne gene therapy and how it drove the stock to its best trading day in a year.

Persons: Ritu Bara, Baral, TD Cowen Organizations: FDA, Biotechnology

☆ Stocks making the biggest moves premarket: Gilead Sciences, Sarepta Therapeutics, Nike and more
▼ + stars: | 2024-06-21 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

The decline comes after the AI chipmaker on Tuesday briefly topped Microsoft as the most valuable public company. Nike — The athletic clothing maker moved 1% higher following an upgrade at Oppenheimer to outperform from market perform. Asana — Shares popped more than 3% after the software firm announced a $150 million share buyback plan. Gilead Sciences — The pharmaceutical stock rose more than 2.6%, building on a rally of 8.5% from the previous session. Delta Air Lines — The stock rose 0.7% following news Thursday that the airliner announced a quarterly dividend of 15 cents a share, a 50% increase from previous levels.

Persons: Oppenheimer, Gilead, LendingTree, Bernstein, Toni Sacconaghi, — CNBC's Brian Evans, Michelle Fox, Jesse Pound, Sarah Min Organizations: Nvidia, Microsoft, Sarepta Therapeutics, U.S . Food, Drug Administration, Nike, Gilead Sciences, Bloomberg, Apple —, Air Lines Locations: U.S, Gilead

Six of the 11 major S&P 500 sectors were trading lower, with information technology (.SPLRCT) leading losses. Pfizer's shares (PFE.N) fell 1.5% after the drugmaker reported its first quarterly loss since 2019. U.S. equities are tracking their third straight month in the red, with the S&P 500 (.SPX) and the Nasdaq (.IXIC) on course for their worst October since 2018. The Fed kicks off a two-day monetary policy meeting on Tuesday. The Fed's commentary on Wednesday would be crucial in assessing how long monetary policy could stay restrictive amid recent signs of economic strength.

Persons: Brendan McDermid, Andrew Hunter, Amruta Khandekar, Shashwat Chauhan, Saumyadeb Chakrabarty, Shounak Dasgupta, Maju Samuel Organizations: New York Stock Exchange, REUTERS, Corp, Dow, Nasdaq, Federal, Nvidia, Microsoft, Caterpillar, Chicago PMI, Capital Economics, Dow Jones, PDD Holdings, VF Corp, Vans, Arista Networks, Sarepta Therapeutics, NYSE, Thomson Locations: New York City, U.S, China, Bengaluru

☆ Sarepta CEO Doug Ingram: We should be profitable by the end of next year if we achieve our goals
▼ + stars: | 2023-06-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSarepta CEO Doug Ingram: We should be profitable by the end of next year if we achieve our goalsDoug Ingram, Sarepta Therapeutics CEO, joins 'Squawk on the Street' to discuss the FDA's concerns with Sarepta's latest approval, how confident Ingram is the company's latest drug approval won't get revoked, and more.

Persons: Doug Ingram, Ingram Organizations: Sarepta Therapeutics

☆ Sarepta slumps as concerns emerge around upcoming gene therapy data
▼ + stars: | 2023-06-23 | by ( ) www.reuters.com time to read: +2 min

June 23 (Reuters) - Sarepta Therapeutics shares (SRPT.O) slumped 11% on Friday as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enough to secure approval for expanded use. The U.S. health regulator had on Thursday granted Sarepta's Elevidys therapy accelerated approval to treat DMD patients aged between 4 and 5 years who can walk, contrary to the company's application for all patients who can walk. Sarepta's gene therapy is the first of its kind for DMD, an inherited progressive muscle-wasting disorder that almost always affects young boys. Elevidys, a one-time treatment, is expected to change the way that DMD patients are treated as current therapies require regular use. William Blair's Tim Lugo called the treatment "transformational for Duchenne's patients" and "a significant opportunity for Sarepta".

Persons: Sarepta's, Gavin Clark, Gartner, William Blair's Tim Lugo, Leroy Leo, Khushi, Devika Organizations: Sarepta Therapeutics, Food and Drug, BioMarin Pharmaceuticals, Thomson Locations: U.S, Bengaluru

☆ FDA reviewers raise doubts over data on Sarepta's gene therapy
▼ + stars: | 2023-05-10 | by ( Leroy Leo | ) www.reuters.com time to read: +2 min

May 10 (Reuters) - The U.S. Food and Drug Administration's staff reviewers raised concerns over limited data on Sarepta Therapeutics Inc's (SRPT.O) gene therapy for a muscle-wasting disorder, ahead of a meeting of the agency's advisers on Friday. The agency's staff on Wednesday highlighted several issues with the data and said that existing studies did not provide "unambigious evidence" that the gene therapy will benefit patients with Duchenne muscular dystrophy. The FDA also highlighted that DMD, a rare disorder that mainly affects young boys, is an urgent unmet medical need. The advisory committee's vote on Friday and an eventual decision by the FDA is seen as a test of the agency's accelerated approval pathway for gene therapies. Sarepta has three drugs available for the disease for people with different types of genetic mutations but they have to be given as weekly intravenous infusion, while the experimental gene therapy is a one-time treatment.

☆ Sarepta drops as report says FDA almost rejected under-review gene therapy
▼ + stars: | 2023-04-13 | by ( ) www.reuters.com time to read: +1 min

April 13 (Reuters) - Sarepta Therapeutics Inc's shares (SRPT.O) fell more than 6% on Thursday as Stat News reported that the U.S. health regulator's staff were inclined to reject the company's gene therapy which is currently under review. Some staff at the U.S. Food and Drug Administration (FDA) had reached a "non-binding conclusion" that Sarepta's gene therapy should not be given approval, prompting FDA official Peter Marks to intervene and instead schedule an advisory meeting on May 12, Stat News reported, citing sources. The company is seeking approval for its gene therapy for treating a rare muscle-wasting disorder called Duchenne muscular dystrophy under the FDA's accelerated pathway. Brokerage William Blair said it still sees a "likely" approval for the therapy. Shares of Catalent Inc (CTLT.N), which holds the contract manufacturing rights for the therapy, fell as much as 5.5% in early trade.

☆ A flurry of news outside the portfolio has implications for 3 of our stocks
▼ + stars: | 2023-04-13 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Here are three noteworthy news developments over the past two days, which contain useful insights about our stocks. For the full year 2023, Novo now expects sales growth in the range of 24% and 30%, compared to prior estimates of 13% to 19%. In addition, operating profit growth is expected to be in the range of 28% and 34%, up from a prior range of 13% to 19%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Sarepta shares tumble as concerns mount over FDA approval on gene therapy
▼ + stars: | 2023-04-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSarepta shares tumble as concerns mount over FDA approval on gene therapyCNBC's Meg Tirrell joins 'Power Lunch' to discuss the Sarepta's gene therapy for muscular dystrophy, and why the stock is taking a tumble over doubts around Sarepta receiving FDA approval.

☆ Morgan Stanley upgrades Sarepta Therapeutics, says biotech stock can rally more than 50%
▼ + stars: | 2023-03-01 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Morgan Stanley thinks that one of Sarepta Therapeutics ' drugs will receive accelerated approval from the Food and Drug Administration — creating a promising investing opportunity. Analyst Matthew Harrison upgraded Sarepta shares to overweight from equal weight, saying that the path for SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy (DMD), now appears "de-risked." Morgan Stanley said that with the accelerated launch of SRP-9001, Sarepta has potential for over $5 billion in peak sales. To be sure, Harrison said potential risks to a downside include updates to the DMD gene therapy program, as well as manufacturing and regulatory risks. Data from competitors could also negatively impact Sarepta's position in the DMD market, the analyst noted.

Search resuls for: "Sarepta's"

11 mentions found